Combining urinary biomarkers improves clinical utility and provides a more robust evaluation
Combining urinary biomarkers allows a complete evaluation of prostate cancer cells while minimizing the risk of missing a foci of cancer or a unique mutation that drives clinical outcomes.
Here, we explore commercially available multiplex urine biomarkers for detecting prostate cancer.
Download the full infographic compliments of Clinical Lab Manager.
Today's Clinical Lab
1000 N West Street, Suite 1200
Wilmington, DE, USA 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@clinicallab.com
©2024 Today's Clinical Lab®
All Rights Reserved
Terms Of Use | Privacy Policy